Chronic Hepatitis

Chronic hepatitis in dogs and cats is a progressive, inflammatory disease of the hepatic parenchyma characterized by hepatocellular apoptosis, necrosis, and variable fibrosis, persisting for more than 3 months. It encompasses a spectrum of histologic patterns including lymphocytic, lymphoplasmacytic, neutrophilic, and granulomatous inflammation, often leading to cirrhosis and hepatic failure. The disease is a major cause of morbidity and mortality in middle-aged to older dogs, with certain breeds showing a genetic predisposition. In cats, chronic hepatitis is often associated with concurrent inflammatory bowel disease and pancreatitis (triaditis). The clinical course is insidious, with many animals presenting in advanced stages. Chronic hepatitis is distinct from acute hepatitis, which has a rapid onset and often resolves or progresses to chronicity. The condition is classified based on etiology (when known) and histopathologic pattern, which guides treatment and prognosis.

The etiology of chronic hepatitis is often idiopathic, but several specific causes have been identified. In dogs, copper-associated hepatopathy is a well-recognized cause, particularly in Bedlington Terriers, West Highland White Terriers, Skye Terriers, Doberman Pinschers, and Labrador Retrievers, due to a defect in biliary copper excretion. Infectious agents include Leptospira spp. (especially L. interrogans serovars), which can cause chronic active hepatitis, and canine adenovirus-1 (CAV-1) historically, though vaccination has reduced its incidence. Chronic hepatitis can also result from drug-induced injury, such as from anticonvulsants (phenobarbital, primidone), nonsteroidal anti-inflammatory drugs (NSAIDs), and certain antibiotics (e.g., trimethoprim-sulfonamide). Toxins like aflatoxins from contaminated food and various plant toxins (e.g., pyrrolizidine alkaloids) are implicated. In cats, chronic hepatitis is often associated with cholangitis, which may be caused by bacterial infection (e.g., E. coli, Enterococcus spp.) ascending from the intestine, and is frequently linked to inflammatory bowel disease and pancreatitis. Autoimmune mechanisms are suspected in many cases, with lymphocytic infiltration targeting hepatocytes. Genetic predispositions are evident in certain breeds, suggesting an inherited susceptibility to immune-mediated damage. Additionally, chronic hepatitis can be a sequel to acute liver injury of any cause, including viral, toxic, or ischemic insults.

Chronic hepatitis is most commonly diagnosed in dogs, with a higher prevalence in middle-aged to older animals (median age 6-10 years). Certain breeds are overrepresented: Bedlington Terriers, West Highland White Terriers, Skye Terriers, Doberman Pinschers, Labrador Retrievers, Cocker Spaniels, and Dalmatians. In cats, chronic hepatitis is less common but often occurs in middle-aged to older cats, with no strong breed predilection, though Siamese and Persian cats may be at higher risk. There is no clear sex predilection in dogs, but some studies suggest a slight female predominance. The incidence of copper-associated hepatitis varies geographically, with higher rates in Europe and North America. Infectious causes like leptospirosis are more common in areas with wildlife reservoirs and in dogs with outdoor access. Drug-induced hepatitis is sporadic and related to specific medication use. The prevalence of chronic hepatitis in the general canine population is estimated at 0.5-1%, but it is a significant cause of referral to specialty hospitals. In cats, chronic hepatitis is often part of triaditis, which is increasingly recognized. The disease is progressive, and without treatment, many animals progress to cirrhosis and hepatic failure within months to years.

The pathophysiology of chronic hepatitis involves a complex interplay of hepatocellular injury, immune activation, and fibrogenesis. Initial injury, whether from copper accumulation, infectious agents, toxins, or drugs, leads to hepatocellular necrosis and apoptosis. Damaged hepatocytes release damage-associated molecular patterns (DAMPs) that activate Kupffer cells (resident macrophages) and recruit circulating inflammatory cells, including lymphocytes, plasma cells, and neutrophils. In copper-associated hepatitis, excessive hepatic copper accumulates in lysosomes, causing oxidative stress and mitochondrial dysfunction, leading to hepatocyte death. The immune response, particularly T-cell-mediated, perpetuates inflammation. CD8+ cytotoxic T cells directly kill hepatocytes, while CD4+ T cells secrete pro-inflammatory cytokines (e.g., TNF-α, IL-1, IL-6) that amplify the inflammatory cascade. Chronic inflammation stimulates hepatic stellate cells (Ito cells) to transform into myofibroblasts, which produce excessive extracellular matrix (collagen), leading to progressive fibrosis. Fibrosis initially occurs in the periportal areas and can progress to bridging fibrosis and ultimately cirrhosis, characterized by nodular regeneration and distortion of hepatic architecture. The loss of functional hepatocytes impairs metabolic, synthetic, and excretory functions, leading to clinical signs such as jaundice, coagulopathy, hypoalbuminemia, and hepatic encephalopathy. Portal hypertension may develop due to fibrosis and increased intrahepatic resistance, leading to ascites, splenomegaly, and acquired portosystemic shunts. In cats, chronic hepatitis is often associated with cholangitis, where inflammation of the biliary epithelium leads to bile duct proliferation and fibrosis, and the inflammatory process may extend to the pancreas and intestine, reflecting a common mucosal immune system.

Predisposing factors for chronic hepatitis include genetic susceptibility, as seen in breeds with inherited copper metabolism defects (e.g., Bedlington Terrier with COMMD1 gene mutation). Age is a risk factor, with middle-aged to older animals more commonly affected. Sex may play a role, with some studies suggesting a higher risk in females. Environmental factors include exposure to infectious agents (Leptospira, CAV-1), hepatotoxic drugs (anticonvulsants, NSAIDs), and dietary factors (excess copper in diet, aflatoxin contamination). Concurrent diseases, such as inflammatory bowel disease in cats, pancreatitis, and endocrine disorders (e.g., diabetes mellitus, hyperadrenocorticism), can predispose to or exacerbate chronic hepatitis. Immunosuppression, whether from disease or medication, may increase susceptibility to infectious causes. In cats, the presence of cholangitis is strongly associated with inflammatory bowel disease, suggesting a gut-liver axis. Obesity and metabolic syndrome may contribute to hepatic lipid accumulation and inflammation, though this is more associated with hepatic lipidosis. Finally, chronic exposure to environmental toxins, such as pesticides and heavy metals, may increase the risk.

Clinical signs of chronic hepatitis are often insidious and may be absent in early stages. As the disease progresses, common signs include lethargy, anorexia, weight loss, vomiting, diarrhea, and polyuria/polydipsia. Physical examination may reveal hepatomegaly or microhepatica (in cirrhosis), jaundice (icterus) of the mucous membranes and skin, and signs of hepatic encephalopathy such as depression, disorientation, circling, and seizures. Ascites may be present due to portal hypertension and hypoalbuminemia. Coagulopathies can manifest as petechiae, ecchymoses, or prolonged bleeding. In advanced stages, signs of liver failure include hypoglycemia, hypotension, and peripheral edema. In cats, chronic hepatitis often presents with similar signs, but may also include ptyalism and weight loss. The clinical signs can be categorized by stage: in the early (subclinical) stage, there may be no overt signs, only laboratory abnormalities. In the moderate stage, intermittent gastrointestinal signs and mild lethargy occur. In the advanced stage, persistent jaundice, ascites, and neurologic signs are prominent. Terminal stage is characterized by severe hepatic failure, coma, and death.

Differential diagnoses for chronic hepatitis include: 1) Acute hepatitis (viral, toxic, or drug-induced) – distinguished by acute onset, history of exposure, and histopathologic findings of predominantly neutrophilic inflammation and necrosis without significant fibrosis. 2) Hepatic lipidosis (especially in cats) – characterized by marked vacuolar hepatocyte change with lipid accumulation, often associated with anorexia, and diagnosed by cytology/histology. 3) Cholangiohepatitis (in cats) – inflammation of bile ducts and surrounding parenchyma, often with neutrophilic or lymphocytic infiltrate, and may be associated with triaditis. 4) Hepatic neoplasia (e.g., hepatocellular carcinoma, lymphoma) – diagnosed by imaging and biopsy, with neoplastic cell populations. 5) Cirrhosis – end-stage fibrosis with nodular regeneration, which is a sequela of chronic hepatitis but may be considered a separate entity. 6) Copper-associated hepatopathy – specifically diagnosed by quantitative copper analysis on liver biopsy. 7) Chronic cholangitis (in cats) – inflammation of bile ducts without significant hepatocellular involvement. 8) Infectious hepatitis (e.g., leptospirosis) – diagnosed by serology, PCR, or culture, and may present with acute renal and hepatic signs. 9) Drug-induced hepatopathy – history of drug administration, with improvement upon withdrawal. 10) Metabolic diseases such as diabetes mellitus or hyperadrenocorticism – may cause hepatic changes but are differentiated by endocrine testing and histopathology. Definitive diagnosis requires liver biopsy, which is the gold standard.

The diagnostic algorithm for chronic hepatitis begins with a thorough history and physical examination, focusing on breed, age, drug exposure, and clinical signs. Initial laboratory tests include a complete blood count (CBC), serum biochemistry profile, and urinalysis. If liver enzyme activities (ALT, AST, ALP, GGT) are elevated, especially with hyperbilirubinemia or hypoalbuminemia, further evaluation is warranted. Next, abdominal ultrasonography is performed to assess liver size, echogenicity, and biliary system, and to guide liver biopsy. Bile acid testing (fasting and postprandial) is recommended to assess liver function. If infectious causes are suspected, serology or PCR for Leptospira, and possibly other agents, should be performed. Coagulation profile (PT, aPTT, platelet count) is essential before biopsy. Definitive diagnosis requires liver biopsy, which can be obtained via ultrasound-guided needle biopsy, laparoscopic biopsy, or surgical wedge biopsy. Histopathology with special stains (e.g., rhodanine for copper) and quantitative copper analysis (if indicated) confirm the diagnosis and guide treatment. In cats, additional testing for pancreatitis (fPLI) and inflammatory bowel disease (intestinal biopsy) may be considered. Advanced imaging (CT or MRI) may be used to evaluate for portosystemic shunts or neoplasia. The diagnostic algorithm should be stepwise, with biopsy being the final confirmatory step.

Laboratory findings in chronic hepatitis are variable and depend on the stage and severity. Hematology may show mild non-regenerative anemia due to chronic disease or blood loss from coagulopathy. Leukocytosis may be present with inflammation, and thrombocytopenia can occur due to decreased production or increased consumption. Serum biochemistry typically reveals elevated liver enzymes: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are often increased, reflecting hepatocellular damage. Alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT) may be elevated, especially with cholestasis. Hyperbilirubinemia (total and direct) indicates impaired bilirubin metabolism or excretion. Hypoalbuminemia occurs with decreased synthetic function. Blood urea nitrogen (BUN) may be low due to decreased urea synthesis. Glucose may be low in advanced disease. Cholesterol may be elevated or decreased. Electrolyte abnormalities include hyponatremia and hypokalemia, often due to gastrointestinal losses. Coagulation abnormalities (prolonged PT and aPTT) may be present due to decreased synthesis of clotting factors. Urinalysis may show bilirubinuria (even with normal serum bilirubin in dogs) and ammonium biurate crystals due to hyperammonemia. Bile acid testing (fasting and 2-hour postprandial) is a sensitive indicator of liver function; elevated values (>25 μmol/L) suggest hepatic dysfunction. Specific biomarkers such as serum bile acids, ammonia, and possibly C-reactive protein (CRP) may be elevated. In copper-associated hepatitis, hepatic copper concentration is increased (>400 ppm dry weight). Serology and PCR for Leptospira can confirm infectious etiology. In cats, feline pancreatic lipase immunoreactivity (fPLI) may be elevated if pancreatitis is present.

Abdominal radiography may show hepatomegaly or microhepatica, but is not specific. Ultrasonography is the primary imaging modality. In chronic hepatitis, the liver may appear normal, enlarged, or reduced in size. Echogenicity is often increased (hyperechoic) due to fibrosis and fatty infiltration, and the parenchyma may be heterogeneous. The hepatic and portal veins may be indistinct. Nodular regeneration may be seen as hypoechoic or hyperechoic nodules. Bile duct dilation may be present if cholangitis is concurrent. Doppler ultrasound can assess portal blood flow and detect portal hypertension. In advanced cirrhosis, acquired portosystemic shunts may be identified. Computed tomography (CT) and magnetic resonance imaging (MRI) provide more detailed assessment of liver architecture, vascular anomalies, and neoplasia, but are not routinely necessary. Endoscopy is not directly useful for liver evaluation, but in cats, duodenoscopy with biopsy may be performed to assess for inflammatory bowel disease. Fluoroscopy is rarely used. In cases of suspected portosystemic shunt, scintigraphy or CT angiography may be indicated.

Cytology from fine-needle aspiration (FNA) of the liver is often non-diagnostic for chronic hepatitis because it only samples a small area and may miss fibrosis or inflammation. However, it can help rule out neoplasia or lipidosis. Histopathology from a biopsy is the gold standard. Findings include lymphocytic or lymphoplasmacytic infiltration in the portal tracts and parenchyma, piecemeal necrosis (interface hepatitis), hepatocellular apoptosis, and variable fibrosis. In copper-associated hepatitis, copper granules can be visualized with rhodanine stain, and quantitative copper analysis is performed on a separate sample. In chronic cholangitis (cats), there is neutrophilic or lymphocytic inflammation of bile ducts with bile duct proliferation. Fibrosis may be graded from mild (portal) to severe (bridging or cirrhosis). Special stains such as Masson's trichrome for collagen and reticulin stains can highlight fibrosis. Histopathologic classification systems (e.g., the WSAVA Liver Standardization Group) provide standardized criteria for diagnosis and grading. Biopsy samples should be obtained from multiple lobes to avoid sampling error.

Treatment of chronic hepatitis is multifaceted and depends on the underlying cause and stage. For copper-associated hepatitis, the primary therapy is copper chelation with D-penicillamine (10-15 mg/kg PO q12h) or trientine (2-4 mg/kg PO q12h), along with a low-copper diet and zinc supplementation (zinc acetate 5-10 mg/kg PO q12h) to reduce intestinal copper absorption. For infectious causes, appropriate antimicrobial therapy is indicated (e.g., doxycycline for leptospirosis). Immunosuppressive therapy is often used for presumed immune-mediated hepatitis: prednisone (1-2 mg/kg PO q12h) or prednisolone, with or without azathioprine (2 mg/kg PO q24h) in dogs; in cats, prednisolone (2-4 mg/kg PO q24h) and chlorambucil (0.1-0.2 mg/kg PO q48h) may be used. Ursodeoxycholic acid (UDCA) (10-15 mg/kg PO q24h) is used as a choleretic and hepatoprotectant. S-adenosylmethionine (SAMe) (20 mg/kg PO q24h) and vitamin E (10-15 IU/kg PO q24h) are antioxidants. Supportive care includes fluid therapy with balanced electrolyte solutions, antiemetics (e.g., maropitant 1 mg/kg SC q24h), and nutritional support with a high-quality, easily digestible diet. In cases of hepatic encephalopathy, lactulose (0.5-1 mL/kg PO q8h) and antibiotics (e.g., neomycin 20 mg/kg PO q8h or metronidazole 7.5 mg/kg PO q12h) are used. Coagulopathy may require vitamin K1 (0.5-1.5 mg/kg SC q12h). In severe cases, hospitalization with intensive care is necessary. Surgical intervention (e.g., liver lobectomy) is rarely indicated except for neoplasia. Dietary management includes low-copper, moderate-protein diets (with high-quality protein) and supplementation with B vitamins. Weight management is important. In cats with triaditis, treatment of concurrent pancreatitis and inflammatory bowel disease is essential.

The prognosis for chronic hepatitis varies widely depending on the etiology, stage at diagnosis, and response to therapy. For copper-associated hepatitis, early diagnosis and treatment can lead to a good prognosis, with many dogs living for years. However, if cirrhosis is present, the prognosis is guarded. For immune-mediated hepatitis, response to immunosuppressive therapy is variable; some dogs achieve remission, while others progress. The median survival time for dogs with chronic hepatitis is reported to be 1-3 years, with factors such as ascites, coagulopathy, and high histologic grade associated with a poorer prognosis. In cats, chronic hepatitis often has a guarded prognosis, especially if associated with triaditis; median survival times are around 1-2 years. Negative prognostic indicators include the presence of cirrhosis, portal hypertension, hepatic encephalopathy, and lack of response to therapy. Serial monitoring of liver enzymes and bile acids can help assess response. With aggressive management, some animals can have a good quality of life for an extended period.

Follow-up for chronic hepatitis involves regular re-evaluations every 2-4 weeks initially, then every 1-3 months once stable. At each visit, a physical examination, body weight, and serum biochemistry profile (including liver enzymes, bilirubin, albumin, glucose, and electrolytes) should be performed. Bile acid testing (fasting and postprandial) is recommended every 3-6 months to assess liver function. Complete blood count and coagulation profile should be monitored, especially if on immunosuppressive therapy. For copper-associated hepatitis, hepatic copper concentration should be re-evaluated after 6-12 months of chelation therapy to guide further treatment. Imaging (ultrasound) may be repeated every 6-12 months to assess progression of fibrosis or cirrhosis. Drug dosages (e.g., immunosuppressants) should be tapered gradually based on clinical and laboratory improvement, with careful monitoring for relapse. Owners should be educated on signs of hepatic encephalopathy and other complications. Long-term management includes dietary modifications, antioxidant supplementation, and avoidance of hepatotoxic drugs. In cats, monitoring for pancreatitis and inflammatory bowel disease is important. The goal is to maintain remission and slow disease progression.

Pearls: 1) Always consider copper-associated hepatitis in predisposed breeds; perform quantitative copper analysis on liver biopsy. 2) Liver biopsy is essential for definitive diagnosis; do not rely solely on laboratory tests. 3) In cats, chronic hepatitis is often part of triaditis; evaluate pancreas and intestines. 4) Use ursodeoxycholic acid and SAMe as adjunctive therapy. 5) Monitor bile acids to assess liver function, not just enzymes. 6) Taper immunosuppressive drugs slowly to avoid relapse. Pitfalls: 1) Failing to perform a biopsy may lead to misdiagnosis and inappropriate treatment. 2) Overlooking infectious causes like leptospirosis can delay appropriate therapy. 3) Using corticosteroids without a definitive diagnosis may worsen infectious or copper-associated hepatitis. 4) Not monitoring for drug side effects (e.g., bone marrow suppression with azathioprine). 5) Ignoring dietary management, especially copper restriction. 6) Underestimating the importance of coagulation testing before biopsy.

Based on Plumb's Veterinary Drug Handbook, the following protocols are commonly used: 1) D-penicillamine: 10-15 mg/kg PO q12h, on an empty stomach, for copper chelation; monitor for vomiting and proteinuria. 2) Trientine: 2-4 mg/kg PO q12h, alternative chelator. 3) Zinc acetate: 5-10 mg/kg PO q12h, to block intestinal copper absorption; monitor for gastrointestinal upset. 4) Prednisone/prednisolone: 1-2 mg/kg PO q12h for dogs, 2-4 mg/kg PO q24h for cats, with gradual taper over months. 5) Azathioprine: 2 mg/kg PO q24h in dogs, often used with corticosteroids; monitor CBC for myelosuppression. 6) Chlorambucil: 0.1-0.2 mg/kg PO q48h in cats, alternative to azathioprine. 7) Ursodeoxycholic acid: 10-15 mg/kg PO q24h, with food. 8) S-adenosylmethionine (SAMe): 20 mg/kg PO q24h, on an empty stomach. 9) Vitamin E: 10-15 IU/kg PO q24h. 10) Lactulose: 0.5-1 mL/kg PO q8h, titrated to produce soft stools. 11) Metronidazole: 7.5 mg/kg PO q12h, for hepatic encephalopathy. 12) Neomycin: 20 mg/kg PO q8h, alternative antibiotic. 13) Vitamin K1: 0.5-1.5 mg/kg SC q12h, for coagulopathy. 14) Maropitant: 1 mg/kg SC q24h, for vomiting. 15) Fluid therapy: balanced crystalloids (e.g., LRS) at maintenance rates, with potassium supplementation as needed. Dosages should be adjusted for renal or hepatic impairment; for example, azathioprine should be used cautiously in hepatic disease. Drug interactions: corticosteroids may increase risk of GI ulceration when combined with NSAIDs; azathioprine and allopurinol interaction can cause severe toxicity.

Key literature includes the WSAVA Liver Standardization Group guidelines (2006) which standardized histopathologic criteria for chronic hepatitis. Studies by Favier et al. (2001) and others have documented copper-associated hepatitis in Bedlington Terriers and the efficacy of D-penicillamine. A study by Webster et al. (2009) evaluated the use of SAMe in canine chronic hepatitis, showing improvement in liver enzymes. The ACVIM consensus statement on leptospirosis (2010) provides guidelines for diagnosis and treatment. In cats, a study by Center et al. (1993) described the association of cholangitis with inflammatory bowel disease. A recent meta-analysis by Dirksen et al. (2017) evaluated the prognosis of chronic hepatitis in dogs, finding a median survival of 1.5 years. The use of ursodeoxycholic acid has been supported by studies showing improved bile flow and hepatoprotection. Immunosuppressive therapy with prednisone and azathioprine is based on clinical experience and retrospective studies, though randomized controlled trials are lacking. Overall, evidence is limited, and treatment is often based on expert opinion and extrapolation from human medicine.